Get the latest tech news
First human trial of regenerative cell therapy for sensorineural hearing loss approved
The University of Sheffield announces approval of the first human trial testing regenerative cell therapy to treat sensorineural hearing loss
Rinri Therapeutics, a leading University of Sheffield spin-out company dedicated to transforming the treatment of sensorineural hearing loss with a regenerative cell therapy, has received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to begin its first-in-human clinical trial. The spin-out company has now developed Rincell-1, designed to regenerate damaged auditory neurons, for which no treatment currently exists, bringing the potential to transform the lives of people with neural hearing loss and to play a significant role in healthy ageing. Simon Chandler, CEO of Rinri Therapeutics, said: “Approval to start our first clinical trial with Rincell-1 in hearing loss is a major milestone and recognition of the potential of our regenerative cell therapy in this area of significant unmet medical need.
Or read this on r/technology
